Clinical Validation of the Role of microRNA Binding Site Mutations in Cancer Risk, Prevention and Treatment

Part of paid clinical trials in Los Angeles, California.

Sponsor
MiraKind
Study ID
NCT02253251
Status
Recruiting
Apply to this trial

Conditions

  • Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • KRAS-variant and microRNA binding site mutation testing — GENETIC
    Participant in these studies will be tested for the KRAS-variant

Study Details

The investigators will recruit and enroll individuals that may have the KRAS-variant or other microRNA binding site mutations to join registry studies. The investigators will allow individuals to obtain their results through a physician at the completion of the studies. The investigators current focus is cancer and autoimmunity.

Key Dates

Start date
Sep 30, 2014
Status verified
Jan 2025
Primary completion
Dec 31, 2030
Completion
Sep 30, 2035

Study Design

Enrollment
15,000 participants (estimated)

Arms

  • Arm: Family Registry
    For individuals identified with the KRAS-variant. Patients will be prospectively followed to determine the impact of lifestyle on disease risk.
  • Arm: Double primary breast cancer
    Women with multiple primary breast cancer will be tested for the KRAS-variant and compared between those with this mutation and those without.
  • Arm: Autoimmunity
    We have shown that the KRAS-variant and other members of this genetic class of mutations associate with altered immunity, leading to immunosuppression as well as autoimmunity.
  • Arm: Cancer patients receiving certain treatments
    We have found that microRNA binding site mutations are predictive biomarkers of outcomes from cancer therapy, including response and toxicity. We will enroll patients to further study and validate these findings.

Primary Outcome Measure

Measuring the prevalence of the KRAS-variant in certain populations Prevalence of the KRAS-variant in BRCA negative breast cancer patients [ Time Frame: 1 year ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
MiraKindLos AngelesCalifornia90025
Joanne Weidhaas, MDPhD
[email protected]
203-671-1308
Joanne Weidhaas
424-387-8100

Find similar trials in Los Angeles, CA

By research site
MiraKind· Los Angeles, CA

Related Studies